ABSORICA - ICON PLC

Manufacturer
ICON PLC
Effective date
2023-03-24
Label type
RISK EVALUATION & MITIGATION STRATEGIES
Version
2
Source
full-release
Hydrated at
2026-06-04 22:50:36

Label at a glance#

ProductABSORICA
Label structure5 sections

Label contents#

Full prescribing information#

I. Administrative Information

REMS ADMINISTRATIVE INFORMATION

Initial Shared System REMS Approval: 10/2010
Most Recent REMS Update: 03/2023

II. REMS Goal

REMS GOALS

The goals of the Isotretinoin REMS are:

  1. To prevent fetal exposure to isotretinoin
  2. To inform prescribers, pharmacists, and patients about isotretinoin’s serious risks and safe use conditions

III. REMS Requirements

REMS REQUIREMENTS

REMS APPLICANT REQUIREMENTS

Isotretinoin Applicants must ensure that healthcare providers, patients, pharmacies, and wholesalers-distributors comply with the following requirements:

1. Healthcare providers who prescribe isotretinoin must:
To become certified to prescribe1. Review the Prescriber Guide.
2. Enroll in the REMS by completing the Prescriber Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first
dose)
3. Assess the patient’s reproductive status using the Prescriber Guide. Document using the Patient Enrollment Form for Patients Who Can Get Pregnant or Patient Enrollment Form for Patients Who Cannot Get Pregnant.
4. For patients who cannot become pregnant: Counsel the patient on the risks of isotretinoin using the Fact Sheet. Document using the Patient Enrollment Form for Patients Who Cannot Get Pregnant.
5. For patients who can become pregnant: Counsel the patient on the risks of isotretinoin using the Fact Sheet and Guide for Patients Who Can Get Pregnant. Document using the Patient Enrollment Form for Patients Who Can Get Pregnant.
6. For patients who can become pregnant: Counsel the patient on the contraception requirements using the Guide for Patients Who Can Get Pregnant and Contraception Counseling Guide or refer the patient for expert counseling. Document using the Patient Enrollment Form for Patients Who Can Get Pregnant.
7. For patients who can become pregnant: Assess the patient’s pregnancy status by ordering and confirming an initial negative pregnancy test result. Document and submit the result to the REMS Program using the Patient Enrollment Form for Patients Who Can Get Pregnant.
8. Enroll the patient by completing and submitting the Patient Enrollment Form for Patients Who Can Get Pregnant or Patient Enrollment Form for Patients Who Cannot Get Pregnant. Provide a copy of the material to the patient.
Before treatment initiation (first
dose); at least 19 days after the
first pregnancy test and in the
first 5 days of the menstrual
period and immediately before
treatment
9. For patients who can become pregnant who have regular menstrual cycles: Assess the patient’s pregnancy status by ordering and confirming a second negative, CLIA-certified pregnancy test result. Document and submit the result to the REMS Program.
Before treatment initiation (first
dose); at least 19 days after the
first pregnancy test and
immediately before treatment
10. For patients who can become pregnant who have amenorrhea, irregular cycles, or use contraceptives that preclude withdrawal bleeding: Assess the patient’s pregnancy status by ordering and confirming a second, negative, CLIA-certified pregnancy test result. Document and submit the result to the REMS Program.
During treatment; before each
prescription
11. Assess the patient’s current reproductive status.
12. For patients who cannot become pregnant: Counsel the patient on the risks of isotretinoin using the Fact Sheet. Document and submit confirmation of counseling to the REMS.
13. For patients who can become pregnant: Counsel the patient on the risks of isotretinoin and program requirements using the Guide for Patients Who Can Get Pregnant and Contraception Counseling Guide. Document and submit confirmation of counseling to the REMS Program.
14. For patients who can become pregnant: Document and submit the patient’s contraception to the REMS Program.
During treatment, within 7 days
before each prescription
15. For patients who can become pregnant: Assess the patient’s pregnancy status by ordering and reviewing a CLIA-certified pregnancy test. Document and submit the results to the REMS Program.
During treatment, on the date
of the last dose
16. For patients who can become pregnant: Assess the patient’s pregnancy status by ordering and reviewing a CLIA-certified pregnancy test. Document and submit the results to the REMS Program.
After treatment discontinuation,
30 days after the date of the
last dose
17. For patients who can become pregnant: Assess the patient’s pregnancy status by ordering and reviewing a CLIA-certified pregnancy test. Document and submit the results to the REMS Program.
To maintain certification to
prescribe, annually
18. Review the Prescriber Guide.
19. Re-activate in the REMS Program by completing the reactivation.
At all times20. Prescribe no more than a 30 days’ supply
21. Not prescribe refills
22. Report pregnancies to the REMS Program.

SPL UNCLASSIFIED SECTION

2. Patients who can become pregnant who are prescribed isotretinoin:
Before treatment initiation, for
30 days
1. Adhere to the safe use condition: use contraception and not get pregnant as described in the Guide for Patients Who Can Get Pregnant.
Before treatment initiation2. Receive counseling from the prescriber on the risks of isotretinoin and the REMS program requirements.
3. Receive counseling from the prescriber or another expert on the contraception requirements.
4. Review the Fact Sheet and Guide for Patients Who Can Get Pregnant.
5. Enroll in the REMS Program by completing the Patient Enrollment Form for Patients Who Can Get Pregnant with the prescriber. Enrollment information will be provided to the REMS Program.
6. Get two pregnancy tests as directed by your prescriber.
During treatment; before each
prescription
7. Receive counseling on the risks of isotretinoin and the REMS program requirements.
8. Get a pregnancy test as directed by your prescriber.
9. Complete the Comprehension Questions.
During treatment, within 7 days
of the last pregnancy test
10. Get your isotretinoin from the pharmacy.
During treatment and after
treatment discontinuation; for
30 days
11. Adhere to safe use conditions: Use contraception as described in the Guide for Patients Who Can Get Pregnant; not take isotretinoin if pregnant, breastfeeding, or not using contraception; not get pregnant; and not donate blood.
At all times12. Inform the prescriber if you become pregnant.
13. Adhere to safe use conditions: Not share isotretinoin.

SPL UNCLASSIFIED SECTION

3. Patients who cannot become pregnant who are prescribed isotretinoin:
Before treatment initiation1. Receive counseling from the prescriber on the risk of isotretinoin and the program requirements.
2. Review the Fact Sheet.
3. Enroll in the REMS Program by completing the Patient Enrollment Form for Patients Who Cannot Get Pregnant with the prescriber. Enrollment information will be provided to the REMS Program.
During treatment; before each
prescription
4. Receive counseling on the risks of isotretinoin and the program requirements.
During treatment; within 30
days of your last office visit
5. Get your isotretinoin from the pharmacy.
During treatment and after
treatment discontinuation; for
30 days
6. Adhere to safe use conditions: Not donate blood.
At all times7. Adhere to safe use conditions: Not share isotretinoin.

SPL UNCLASSIFIED SECTION

4. Pharmacies that dispense isotretinoin must:
To become certified to dispense1. Designate an authorized representative to carry out the certification process and oversee implementation and compliance with the REMS Program on behalf of the pharmacy.
2. Have the authorized representative review the Pharmacist Guide.
3. Have the authorized representative enroll in the REMS Program by completing the Pharmacy Enrollment Form and submitting it to the REMS Program.
4. Train all relevant staff involved in dispensing using the Pharmacist Guide.
5. Establish processes and procedures to document the authorization number for each prescription.
6. Establish processes and procedures to not dispense an isotretinoin prescription after the date provided by the REMS Program, and to reverse the authorization to dispense the prescription if needed, and steps to return isotretinoin to inventory.
Before dispensing7. Obtain authorization to dispense each prescription by contacting the REMS Program to verify the prescriber is certified, the patient is enrolled, the patient counseling is complete, and dispensing is within the designated timeframe. For patients who can become pregnant: the patient is not pregnant, the patient’s contraception is confirmed, and the patient’s monthly comprehension questions are complete.
8. Document the authorization number for each prescription through the processes and procedures established as a requirement of the REMS Program.
To maintain certification to
dispense, annual
9. Have the authorized representative re-enroll in the REMS Program.
At all times10. Not dispense more than a 30 days’ supply.
11. Not dispense refills.
12. Not dispense after the date provided by the REMS Program, reverse the authorization to dispense, and return isotretinoin to inventory through the processes and procedures established as a requirement of the REMS program.
13. Return unused product to the manufacturer.
14. Not distribute, transfer, loan, or sell isotretinoin.
15. Comply with audits carried out by the Isotretinoin Applicants, or a third party acting on behalf of the Isotretinoin Applicants to ensure that all processes and procedures are in place and are being followed.

SPL UNCLASSIFIED SECTION

5. Wholesalers-distributors that distribute isotretinoin must:
To be able to distribute1. Establish processes and procedures to ensure that the drug is distributed only to certified pharmacies and authorized wholesalers with written consent from the isotretinoin manufacturer.
2. Train all relevant staff involved in distributing isotretinoin on the program requirements.
At all times3. Distribute only to certified pharmacies and authorized wholesalers with written consent from the isotretinoin manufacturer.
4. Notify isotretinoin manufacturers of non-certified pharmacies or unauthorized wholesalers-distributors that attempt to order isotretinoin.
5. Return unused product to the manufacturer.
6. Maintain records of distribution information.
7. Comply with audits carried out by the Isotretinoin Applicants, or third party acting on behalf of the Isotretinoin Applicants to ensure that all processes and procedures are in place and are being followed.

SPL UNCLASSIFIED SECTION

Isotretinoin Applicants must provide training to healthcare providers who prescribe isotretinoin.
The training must include the following educational materials: Prescriber Guide. The training must be available on the REMS Program website and available in a hardcopy format via mail.

Isotretinoin Applicants must provide training to pharmacies that dispense isotretinoin.
The training must include the following educational materials: Pharmacist Guide. The training must be available on the REMS Program website and available in a hardcopy format via mail.

To inform healthcare providers about the REMS Program and the risks and safe use of isotretinoin, Isotretinoin Applicants must disseminate REMS communication materials according to the table below:

Target AudienceCommunication Materials & Dissemination Plans
Prescribers certified in
the Isotretinoin REMS
REMS Letter: Prescriber Communication Letter
  1. Email within 180 calendar days of approval of the REMS modification.
Healthcare providers
likely to prescribe
Isotretinoin
REMS Letter: Medical Organizations Communication Letter
  1. Email within 180 calendar days of approval of the REMS modification to the following professional organizations and request the letter or content be provided to their members:
    a. American Academy of Dermatology, Society of Dermatology Physician Assistants
Healthcare Providers
and Designees
Website Program Update
  1. Publish prominently on the public homepage at ipledgeprogram.com within 180 calendar days of approval of the REMS modification. Display for 60 calendar days.
Website Pop-Up Message
  1. Publish prominently on the public homepage at ipledgeprogram.com on the within 180 calendar days of approval of the REMS modification and display for 60 calendar days. The Message must appear with the first 7 visits to the homepage and require an active click to close it.

To support REMS Program operations, Isotretinoin Applicants must:

  1. Establish and maintain a REMS Program website, ipledgeprogram.com. The REMS Program website must include the capability to complete prescriber and pharmacy enrollment online, to enroll and manage patients online, and the option to print the Prescribing Information, Medication Guide, and the REMS materials. All product websites for consumers and healthcare providers must include prominent REMS-specific links to the REMS Program website. The REMS Program website must not link back to the promotional product website(s).
  2. Make the REMS Program website fully operational and all REMS materials available through the REMS website and call center within 180 calendar days of REMS Modification (September 24, 2023).
  3. Establish and maintain a REMS Program call center for REMS participants at 866-495-0654.
  4. Establish and maintain a validated, secure database of all REMS participants who are enrolled and/or certified in the REMS Program.
  5. Ensure prescribers and pharmacies are able to enroll online and by phone.
  6. Ensure prescribers are able to enroll patients online and by phone.
  7. Ensure prescribers are able to report the patient’s reproductive status, change in reproductive status, pregnancy test results, contraception choices to qualify patients to receive isotretinoin online and by phone.
  8. Ensure prescribers are able to enroll designees online using the Office Staff Designees Activation Form.
  9. Ensure prescribers are able to request an exemption on behalf of patients with a serious medical reason from the initial pregnancy testing requirements online and by fax using the Exemption for Patients with Serious Medical Reasons Who Can Get Pregnant.
  10. Ensure patients who can become pregnant are able to complete the Comprehension Questions online and by phone.
  11. Ensure pharmacies are able to obtain authorization to dispense online and by phone. For patients who can become pregnant, the authorization is valid for 7 days from the date of the specimen collection for the pregnancy test. For patients who cannot become pregnant, the authorization is valid for 30 days from the date of the last office visit and be provided with the date not to dispense isotretinoin after.
  12. Ensure prescribers are able to report pregnancies online and by phone.
  13. Ensure patients are able to report pregnancies by phone.
  14. Provide Prescriber Enrollment Form, Prescriber Guide, and the Prescribing Information to Healthcare Providers who (1) attempt to prescribe isotretinoin and are not yet certified or (2) inquire about how to become certified.
  15. Provide Recognizing Psychiatric Disorders in Adolescents and Young Adults to healthcare providers upon request.
  16. Provide certified prescribers access to the database of enrolled patients and certified pharmacies.
  17. Provide pharmacies access to the database of enrolled patients and certified prescribers.
  18. Establish and maintain a registry which includes a reporting and collection system for all patients who become pregnant to provide information on pregnancy outcomes and root cause of pregnancy.
  19. Ensure that once a report suggestive of pregnancy is received, the Isotretinoin Applicants follow up to obtain all required data for the registry.

To ensure REMS participants compliance with the REMS Program, Isotretinoin Applicants must:

  1. Maintain adequate records to demonstrate that REMS requirements have been met, including, but not limited to records of isotretinoin distribution and dispensing, certification of prescribers and pharmacies, enrolled patients, and audits of REMS participants. These records must be readily available for FDA inspections.
  2. Establish and maintain a plan for addressing noncompliance with REMS Program requirements, Non-Compliance Action Policy.
  3. Monitor prescribers and their designees, pharmacies, patients, and wholesalers-distributors on an ongoing basis to ensure the requirements are being met. Take corrective action if noncompliance is identified, including de-certification and disenrollment.
  4. Monitor and ensure that patients have been assigned correctly to one of the following patient risk categories. Confirm risk category during the patient enrollment process:
    • Patients who can become pregnant: cisgender females (born a female with a uterus and at least one ovary), transgender males (born female with a uterus and at least one ovary, transitioned to a male).
    • Patients who cannot become pregnant: cisgender male (born a male), cisgender females and transgender males that have undergone a hysterectomy, cisgender females and transgender males that have undergone a bilateral oophorectomy, cisgender females and transgender males who are post-menopausal according to the Prescriber Guide, transgender female (born male and transitioned to female).
  5. Audit 10% of certified pharmacies annually (maximum 400) that have ordered isotretinoin in the previous 12 months to ensure that all processes and procedures are in place, functioning, and support the REMS Program requirements.
  6. Audit wholesalers-distributors no later than 180 calendar days after the wholesaler-distributor is authorized and annually thereafter to ensure that all processes and procedures are in place, functioning, and support the REMS Program requirements. The annual audit must include all wholesalers-distributors that distributed isotretinoin in the previous 12 months.
  7. Take reasonable steps to improve implementation and compliance with the requirements in the Isotretinoin REMS Program based on monitoring and evaluation of the Isotretinoin REMS Program.

IV. REMS Assessment Timetable

REMS TIMETABLE FOR SUBMISSION ASSESSMENTS

Isotretinoin NDA Applicants must submit REMS assessments to the FDA on March 1, 2024, and every two years thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 calendar days before the submission date for that assessment. Isotretinoin NDA Applicants must submit each assessment so that it will be received by the FDA on or before the due date.

V. REMS Materials

REMS MATERIAL

The following materials are part of the Isotretinoin REMS Program:

Enrollment Forms
Prescriber
                1. Prescriber Enrollment Form

Patient
                2. Patient Enrollment Form for Patients Who Can Get Pregnant
                3. Patient Enrollment Form for Patients Who Cannot Get Pregnant

Pharmacy
                4. Pharmacy Enrollment Form

Training and Educational Materials
Prescriber
                5. Prescriber Guide
Patient
                6. Guide for Patients Who Can Get Pregnant
                7. Fact Sheet
                8. Contraception Counseling Guide
                9. Comprehension Questions

Pharmacy
                10. Pharmacist Guide

Patient Care Forms
                11. Exemption for Patients with Serious Medical Reasons Who Can Get Pregnant

Communication Materials
                12. Prescriber Communication Letter
                13. Medical Organizations Communication Letter
                14. Website Program Update
                15. Website Pop-Up Message

Other
                16. REMS Program Website
                17. Office Staff Designees Activation Form
                18. Recognizing Psychiatric Disorders in Adolescents and Young Adults
                19. Non-Compliance Action Policy

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8300c0f6-79a4-735b-88ec-d781bfffdb10Product name520260305
644afe93-ba9b-4043-8e40-a9fe9af2d5d7Product name220250616
e5fedfa5-6b96-4769-872b-95d1e7f3a85aProduct name120200415

DailyMed REMS / Drug Safety Documents#

Labels related to this REMS document

DailyMed label, Relation, Version table
DailyMed labelRelationVersionEffectiveManufacturerSource
These highlights do not include all the information needed to use ZENATANE safely and effectively. See full prescribing information for ZENATANE . ZENATANE (isotretinoin) capsules, for oral use Initial U.S. Approval: 1982SPL related document2026-09-20Dr. Reddy's Laboratories Limited | Dr. Reddy's Laboratories Limited FTO-SEZ-Process Unit-02 | Reed-Lane Inc.20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES. ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982SPL related document2026-08-27Amneal Pharmaceuticals LLC | Amneal Pharmaceuticals of New York, LLC20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES. ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982SPL related document2026-08-20Actavis Pharma, Inc.20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use ABSORICA/ABSORICA LD safely and effectively. See full prescribing information for ABSORICA/ABSORICA LD. ABSORICA ® (isotretinoin) capsules, for oral use ABSORICA LD ® (isotretinoin) capsules, for oral use Initial U.S. Approval: 1982SPL related document2026-08-19Sun Pharmaceutical Industries, Inc. | Galephar Pharmaceutical Research Inc. | Ohm Laboratories Inc.20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use AMNESTEEM ® safely and effectively. See full prescribing information for AMNESTEEM ® . AMNESTEEM ® (Isotretinoin Capsules), for oral use Initial U.S. Approval: 1982SPL related document2026-08-15Mylan Pharmaceuticals Inc.20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use CLARAVIS safely and effectively. See full prescribing information for CLARAVIS. CLARAVIS™ (isotretinoin capsules), for oral use Initial U.S. Approval: 1982SPL related document2026-07-22Teva Pharmaceuticals USA, Inc.20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES. ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982SPL related document2022-11-03Mayne Pharma20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml
These highlights do not include all the information needed to use ISOTRETINOIN CAPSULES safely and effectively. See full prescribing information for ISOTRETINOIN CAPSULES. ISOTRETINOIN capsules, for oral use Initial U.S. Approval: 1982SPL related document2022-10-24Upsher-Smith Laboratories, LLC20230912_f69fc1c7-4a89-444e-b664-1753f79ffd92.zip!60e57ef1-7470-447f-8e38-44167b99870d.xml

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Absorica LDISOTRETINOINSun Pharmaceutical Industries, Inc.3ef0cff8-19c1-4441-b780-fca6c7ee16152026-08-19Boxed warning, Warnings, Adverse reactionsName fallback
brand name: Absorica

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.